How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
31
EBS Quote, Financials, Valuation and Earnings
Last price:
$11.34
Seasonality move
:
-7.78%
Day range:
$11.29 - $12.05
52-week range:
$4.02 - $14.06
Dividend yield:
0%
P/E ratio:
8.76x
P/S ratio:
0.80x
P/B ratio:
1.02x
Volume:
566.9K
Avg. volume:
894.8K
1-year change:
2.07%
Market cap:
$595.6M
Revenue:
$1B
EPS (TTM):
$1.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$295M | $0.11 | 23.76% | -94.67% | $13.50 |
|
BDTX
Black Diamond Therapeutics, Inc.
|
-- | -$0.20 | -86.61% | -93.68% | $9.29 |
|
BSX
Boston Scientific Corp.
|
$5.6B | $0.87 | 11.57% | 76.14% | $124.41 |
|
IRON
Disc Medicine, Inc.
|
$4.6M | -$1.69 | -- | -84.62% | $122.08 |
|
LLY
Eli Lilly & Co.
|
$18.9B | $8.05 | 35.51% | 147.92% | $1,146.30 |
|
PEN
Penumbra, Inc.
|
$387.6M | $1.20 | 14.25% | 8.28% | $348.53 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$11.34 | $13.50 | $595.6M | 8.76x | $0.00 | 0% | 0.80x |
|
BDTX
Black Diamond Therapeutics, Inc.
|
$2.49 | $9.29 | $141.9M | 6.86x | $0.00 | 0% | 2.03x |
|
BSX
Boston Scientific Corp.
|
$93.53 | $124.41 | $138.7B | 50.03x | $0.00 | 0% | 7.22x |
|
IRON
Disc Medicine, Inc.
|
$77.32 | $122.08 | $2.9B | -- | $0.00 | 0% | -- |
|
LLY
Eli Lilly & Co.
|
$1,037.15 | $1,146.30 | $928.3B | 51.29x | $1.50 | 0.58% | 15.91x |
|
PEN
Penumbra, Inc.
|
$358.17 | $348.53 | $14.1B | 85.60x | $0.00 | 0% | 10.52x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
53.53% | 4.542 | 144.36% | 2.93x |
|
BDTX
Black Diamond Therapeutics, Inc.
|
13.49% | 5.149 | 9.11% | 8.72x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.384 | 8.31% | 0.81x |
|
IRON
Disc Medicine, Inc.
|
5.13% | 1.446 | 1.34% | 23.03x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.496 | 6.22% | 0.65x |
|
PEN
Penumbra, Inc.
|
13.77% | -0.892 | 2.19% | 3.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EBS
Emergent BioSolutions, Inc.
|
$129.1M | $76.8M | 6.29% | 14.25% | 33.23% | -$5.7M |
|
BDTX
Black Diamond Therapeutics, Inc.
|
-$86K | -$11M | 15.62% | 18.5% | 77.9% | -$7.9M |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
IRON
Disc Medicine, Inc.
|
-$87K | -$67.7M | -31.4% | -32.82% | -- | -$47.8M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
PEN
Penumbra, Inc.
|
$238M | $48.8M | 11.35% | 13.4% | 13.77% | $42M |
Emergent BioSolutions, Inc. vs. Competitors
-
Which has Higher Returns EBS or BDTX?
Black Diamond Therapeutics, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of 80.77%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Black Diamond Therapeutics, Inc.'s return on equity of 18.5%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B BDTXBlack Diamond Therapeutics, Inc.-- -$0.15 $145.8M -
What do Analysts Say About EBS or BDTX?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 19.05%. On the other hand Black Diamond Therapeutics, Inc. has an analysts' consensus of $9.29 which suggests that it could grow by 272.92%. Given that Black Diamond Therapeutics, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Black Diamond Therapeutics, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 BDTXBlack Diamond Therapeutics, Inc.6 1 0 -
Is EBS or BDTX More Risky?
Emergent BioSolutions, Inc. has a beta of 2.300, which suggesting that the stock is 129.997% more volatile than S&P 500. In comparison Black Diamond Therapeutics, Inc. has a beta of 3.396, suggesting its more volatile than the S&P 500 by 239.585%.
-
Which is a Better Dividend Stock EBS or BDTX?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Black Diamond Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Black Diamond Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or BDTX?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than Black Diamond Therapeutics, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Black Diamond Therapeutics, Inc.'s net income of -$8.5M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.76x while Black Diamond Therapeutics, Inc.'s PE ratio is 6.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.80x versus 2.03x for Black Diamond Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.80x 8.76x $231.1M $51.2M BDTXBlack Diamond Therapeutics, Inc.2.03x 6.86x -- -$8.5M
-
Which has Higher Returns EBS or BSX?
Boston Scientific Corp. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of 14.91%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About EBS or BSX?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 19.05%. On the other hand Boston Scientific Corp. has an analysts' consensus of $124.41 which suggests that it could grow by 33.01%. Given that Boston Scientific Corp. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Boston Scientific Corp. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 BSXBoston Scientific Corp.26 1 0 -
Is EBS or BSX More Risky?
Emergent BioSolutions, Inc. has a beta of 2.300, which suggesting that the stock is 129.997% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.
-
Which is a Better Dividend Stock EBS or BSX?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or BSX?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Emergent BioSolutions, Inc.'s net income of $51.2M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.76x while Boston Scientific Corp.'s PE ratio is 50.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.80x versus 7.22x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.80x 8.76x $231.1M $51.2M BSXBoston Scientific Corp.7.22x 50.03x $5.1B $755M
-
Which has Higher Returns EBS or IRON?
Disc Medicine, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of --. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Disc Medicine, Inc.'s return on equity of -32.82%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B IRONDisc Medicine, Inc.-- -$1.77 $604.4M -
What do Analysts Say About EBS or IRON?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 19.05%. On the other hand Disc Medicine, Inc. has an analysts' consensus of $122.08 which suggests that it could grow by 57.89%. Given that Disc Medicine, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Disc Medicine, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 IRONDisc Medicine, Inc.11 0 0 -
Is EBS or IRON More Risky?
Emergent BioSolutions, Inc. has a beta of 2.300, which suggesting that the stock is 129.997% more volatile than S&P 500. In comparison Disc Medicine, Inc. has a beta of 0.870, suggesting its less volatile than the S&P 500 by 13.012%.
-
Which is a Better Dividend Stock EBS or IRON?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Disc Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Disc Medicine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or IRON?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are larger than Disc Medicine, Inc. quarterly revenues of --. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Disc Medicine, Inc.'s net income of -$62.3M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.76x while Disc Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.80x versus -- for Disc Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.80x 8.76x $231.1M $51.2M IRONDisc Medicine, Inc.-- -- -- -$62.3M
-
Which has Higher Returns EBS or LLY?
Eli Lilly & Co. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of 31.72%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About EBS or LLY?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 19.05%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,146.30 which suggests that it could grow by 9.33%. Given that Emergent BioSolutions, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Emergent BioSolutions, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 LLYEli Lilly & Co.17 7 0 -
Is EBS or LLY More Risky?
Emergent BioSolutions, Inc. has a beta of 2.300, which suggesting that the stock is 129.997% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.
-
Which is a Better Dividend Stock EBS or LLY?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios EBS or LLY?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Emergent BioSolutions, Inc.'s net income of $51.2M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.76x while Eli Lilly & Co.'s PE ratio is 51.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.80x versus 15.91x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.80x 8.76x $231.1M $51.2M LLYEli Lilly & Co.15.91x 51.29x $17.6B $5.6B
-
Which has Higher Returns EBS or PEN?
Penumbra, Inc. has a net margin of 22.16% compared to Emergent BioSolutions, Inc.'s net margin of 12.93%. Emergent BioSolutions, Inc.'s return on equity of 14.25% beat Penumbra, Inc.'s return on equity of 13.4%.
Company Gross Margin Earnings Per Share Invested Capital EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B PENPenumbra, Inc.67.1% $1.17 $1.6B -
What do Analysts Say About EBS or PEN?
Emergent BioSolutions, Inc. has a consensus price target of $13.50, signalling upside risk potential of 19.05%. On the other hand Penumbra, Inc. has an analysts' consensus of $348.53 which suggests that it could fall by -2.69%. Given that Emergent BioSolutions, Inc. has higher upside potential than Penumbra, Inc., analysts believe Emergent BioSolutions, Inc. is more attractive than Penumbra, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EBSEmergent BioSolutions, Inc.2 0 0 PENPenumbra, Inc.2 13 1 -
Is EBS or PEN More Risky?
Emergent BioSolutions, Inc. has a beta of 2.300, which suggesting that the stock is 129.997% more volatile than S&P 500. In comparison Penumbra, Inc. has a beta of 0.714, suggesting its less volatile than the S&P 500 by 28.599%.
-
Which is a Better Dividend Stock EBS or PEN?
Emergent BioSolutions, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Penumbra, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions, Inc. pays -- of its earnings as a dividend. Penumbra, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EBS or PEN?
Emergent BioSolutions, Inc. quarterly revenues are $231.1M, which are smaller than Penumbra, Inc. quarterly revenues of $354.7M. Emergent BioSolutions, Inc.'s net income of $51.2M is higher than Penumbra, Inc.'s net income of $45.9M. Notably, Emergent BioSolutions, Inc.'s price-to-earnings ratio is 8.76x while Penumbra, Inc.'s PE ratio is 85.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions, Inc. is 0.80x versus 10.52x for Penumbra, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EBSEmergent BioSolutions, Inc.0.80x 8.76x $231.1M $51.2M PENPenumbra, Inc.10.52x 85.60x $354.7M $45.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
